Literature DB >> 20224718

High-level cervical spinal cord stimulation used to treat intractable pain arising from transverse myelitis caused by schistosomiasis.

Jin Kyung Kim1, Seok Ho Hong, Jung-Kyo Lee.   

Abstract

The efficacy of spinal cord stimulation (SCS) for treatment of various chronic painful conditions is well established. Very few reports have documented the use of SCS for treatment of chronic pain after spinal cord injury. We present a case showing a good outcome after such treatment, and suggest that high cervical stimulation may be efficacious. A 53-year-old male underwent SCS on the C1-3 level for treatment of intractable neuropathic pain below the T3 level, and in the upper extremities, arising from spinal cord injury resulting from transverse myelitis caused by schistosomiasis. High cervical SCS significantly improved the pain in the upper extremities and at the T3-T10 dermatome level. The patient continues to report excellent pain relief 9 months later. The present case suggests that high cervical stimulation may improve chronic pain in the upper extremities and the T3-T10 dermatome level arising from spinal cord injury.

Entities:  

Keywords:  Schistosomiasis; Spinal cord injury; Spinal cord stimulation; Transverse myelitis

Year:  2010        PMID: 20224718      PMCID: PMC2836454          DOI: 10.3340/jkns.2010.47.2.151

Source DB:  PubMed          Journal:  J Korean Neurosurg Soc        ISSN: 1225-8245


  22 in total

Review 1.  Schistosomiasis.

Authors:  Allen G P Ross; Paul B Bartley; Adrian C Sleigh; G Richard Olds; Yuesheng Li; Gail M Williams; Donald P McManus
Journal:  N Engl J Med       Date:  2002-04-18       Impact factor: 91.245

2.  Cervical spinal cord stimulation in cerebral ischemia.

Authors:  C D Upadhyaya; O Sagher
Journal:  Acta Neurochir Suppl       Date:  2007

3.  Effective cervical spinal cord stimulation for bilateral lower extremities pain: technical report.

Authors:  Leonardo Kapural; Jacek Cywinski; Paulina Zovkic; Michael Stanton-Hicks
Journal:  Pain Pract       Date:  2008 Mar-Apr       Impact factor: 3.183

4.  Spinal cord stimulator relieves neuropathic pain in a patient with radiation-induced transverse myelitis.

Authors:  Basem Hamid; Naeem Haider
Journal:  Pain Pract       Date:  2007-11-06       Impact factor: 3.183

5.  Spinal cord stimulation in the treatment of paraplegic pain.

Authors:  B Cioni; M Meglio; L Pentimalli; M Visocchi
Journal:  J Neurosurg       Date:  1995-01       Impact factor: 5.115

6.  Mapping of sensory responses to epidural stimulation of the intraspinal neural structures in man.

Authors:  G Barolat; F Massaro; J He; S Zeme; B Ketcik
Journal:  J Neurosurg       Date:  1993-02       Impact factor: 5.115

Review 7.  Safety and efficacy of spinal cord stimulation for the treatment of chronic pain: a 20-year literature review.

Authors:  Tracy Cameron
Journal:  J Neurosurg       Date:  2004-03       Impact factor: 5.115

Review 8.  Mechanisms of chronic central neuropathic pain after spinal cord injury.

Authors:  Claire E Hulsebosch; Bryan C Hains; Eric D Crown; Susan M Carlton
Journal:  Brain Res Rev       Date:  2008-12-25

Review 9.  Management of neuropathic pain following spinal cord injury: now and in the future.

Authors:  P J Siddall
Journal:  Spinal Cord       Date:  2008-11-11       Impact factor: 2.772

10.  C1-c2 sublaminar insertion of paddle leads for the management of chronic painful conditions of the upper extremity.

Authors:  Louis A Whitworth; Claudio A Feler
Journal:  Neuromodulation       Date:  2003-07
View more
  2 in total

1.  Relief of Neuropathic Pain After Spinal Cord Stimulator Implantation in a Patient With Idiopathic Thoracic Transverse Myelitis: A Case Report.

Authors:  Rajiv Reddy; Rupa Prasad; Sepehr Rejai; Kenneth Halter; Jeffrey Chen
Journal:  A A Pract       Date:  2019-12-01

2.  Intrathecal drug delivery to treat intractable neuropathic pain following Sjögren's syndrome-induced transverse myelitis: A case report.

Authors:  Ji Yeong Kim; Yong Ho Lee; Ji Young Kim; Hyun Hwa Lee; Young Hoon Kim
Journal:  Medicine (Baltimore)       Date:  2021-06-04       Impact factor: 1.817

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.